J. Nikkilä

发表

Breast Cancer–Associated Abraxas Mutation Disrupts Nuclear Localization and DNA Damage Response Functions

Katri Pylkäs, Arto Mannermaa, Jaana M. Hartikainen, 2012, Science Translational Medicine.

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

J. Armenia, A. Lau, M. O’Connor, 2021, Molecular Cancer Therapeutics.

BRD4 facilitates replication stress-induced DNA damage response

G. Mills, A. Dulak, A. Lau, 2018, Oncogene.

A recurrent mutation in PALB2 in Finnish cancer families

Katri Pylkäs, Arja Jukkola-Vuorinen, Mervi Grip, 2007, Nature.

PALB2 and RAP80 genes in hereditary breast cancer predisposition

J. Nikkilä, 2013 .

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells

A. Ashworth, S. Pettitt, C. Lord, 2017, British Journal of Cancer.

Elevated APOBEC 3 B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p 53-defective cells

A. Ashworth, S. Pettitt, C. Lord, 2017 .

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

G. Mills, C. Caldas, J. Barrett, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Heterozygous mutations in PALB2 cause DNA replication and damage response defects

H. Pospiech, R. Winqvist, K. Pylkäs, 2013, Nature Communications.

Screening for large genomic rearrangements in the FANCA gene reveals extensive deletion in a Finnish breast cancer family.

R. Winqvist, K. Pylkäs, P. Hirvikoski, 2011, Cancer letters.

Inactivation of Palb2 gene leads to mesoderm differentiation defect and early embryonic lethality in mice.

R. Winqvist, K. Pylkäs, M. Poutanen, 2010, Human molecular genetics.

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

M. O’Connor, S. Fawell, B. Davies, 2019, Nature Communications.

Penetrance Analysis of the PALB2 c.1592delT Founder Mutation

J. Hopper, M. Southey, A. Mannermaa, 2008, Clinical Cancer Research.

Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families

Katri Pylkäs, Robert Winqvist, R. Winqvist, 2008, BMC Cancer.

Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles

Fiona Pachl, M. O’Connor, Glen Hawthorne, 2018, Experimental and Molecular Therapeutics.

Szilvia Solyom Localization and DNA Damage Response Functions Mutation Disrupts Nuclear Abraxas Associated − Breast Cancer

A. Mannermaa, V. Kosma, J. Hartikainen, 2012 .

Familial breast cancer screening reveals an alteration in the RAP80 UIM domain that impairs DNA damage response function

R. Greenberg, R. Winqvist, K. Pylkäs, 2009, Oncogene.

Mutation analysis of the AATF gene in breast cancer families

Katri Pylkäs, Robert Winqvist, R. Winqvist, 2009, BMC Cancer.